Anaplastic Lymphoma Kinase (ALK) and p53 Are Potentially Useful Markers to Distinguish Inflammatory Myofibroblastic Tumor


Aims: Inflammatory myofibroblastic tumor (IMT) of the urinary bladder is a clinically and histologically uncommon benign tumor that can be easily mistaken for a malignant neoplasm. We sought to determine whether immunohistochemical staining would be evaluated IMT of the urinary bladder. We have also shown the literatures that imminohistochemical staining of IMT was investigated to distinguish malignant lesions using PubMed data base. Methods: Immunohistochemical staining, including anaplastic lymphoma kinase (ALK), p53, cytokeratin, vimentin, desmin, alpha-smooth muscle actin, myoglobin, smooth muscle myosin and S100, was carried out on serial sections from archival specimens of three patients who underwent transurethral resection and partial cystectomy. Results: Immunohistchemical staining in all patients was positive for ALK and weak positive for p53 protein. In the literatures, positive rates of ALK and p53 inthe IMT of the urinary bladder were 60.9% and 53.1%, respectively. Sarcoma and carcinosarcoma were shown in the pathological specimens with negative ALK and strongly positive p53 inthe same data base. Conclusions: Both ALK and p53 were potentially useful protein markers to distinguish between IMT and sarcoma. However, this study was small sample size. Further study was warranted an investigation of the availability of these proteins in IMT.

Share and Cite:

S. Kurosaka, K. Matsumoto, A. Irie, T. Hirayama, M. Nishi, T. Fujita, T. Satoh, Y. Sato, M. Iwamura and K. Yoshida, "Anaplastic Lymphoma Kinase (ALK) and p53 Are Potentially Useful Markers to Distinguish Inflammatory Myofibroblastic Tumor," Open Journal of Urology, Vol. 3 No. 2, 2013, pp. 71-74. doi: 10.4236/oju.2013.32014.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. K. Chan, W. Cheuk and M. Shimizu, “Anaplastic Lymphoma Kinase Expression in Inflammatory Pseudotumors,” American Journal of Surgical Pathology, Vol. 25, No. 6, 2001, pp. 761-768. doi:10.1097/00000478-200106000-00007
[2] T. Tsuzuki, C. Magi-Galluzzi and J. I. Epstein, “ALK-1 Expression in Inflammatory Myofibroblastic Tumor of the Urinary Bladder,” American Journal of Surgical Pathology, Vol. 28, No. 12, 2004, pp. 1609-1614. doi:10.1097/00000478-200412000-00009
[3] S. W. Morris, M. N. Kirstein, M. B. Valentine, K. G. Dittmer, D. N. Shapiro, D. L. Saltman and A. T. Look, “Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma,” Science Magazine, Vol. 263, No. 5151, 1994, pp. 1281-1284. doi:10.1126/science.8122112
[4] C. M. Coffin, L. P. Dehner, J. M. Meis-Kindblom and S. Diagn, “Inflammatory Myofibroblastic Tumor, Inflammatory Fibrosarcoma, and Related Lesions: An Historical Review with Differential Diagnostic Considerations,” Seminars in Diagnostic Pathology, Vol. 15, No. 2, 1998, pp. 102-110.
[5] J. W. Hussong, M. Brown, S. L. Perkins, L. P. Dehner and C. M. Coffin, “Comparison of DNA Ploidy, Histologic, and Immunohistochemical Findings with Clinical Outcome in Inflammatory Myofibroblastic Tumors,” Modern Pathology, Vol. 12, No. 3, 1999, pp. 279-286.
[6] J. A. Roth, “Reactive Pseudosarcomatous Response in Urinary Bladder,” Urology, Vol. 16, No. 6, 1980, pp. 635-637. doi:10.1016/0090-4295(80)90578-6
[7] M. Hisaoka, S. Shimajiri, Y. Matsuki, J. M. Meis-Kindblom, L. G. Kindblom, X. Q. Li, J. Wang and H. Hashimoto, “Inflammatory Myofibroblastic Tumor with Predominant Anaplastic Lymphoma Kinase-Positive Cells Lacking a Myofibroblastic Phenotype,” Pathology International, Vol. 53, No. 6, 2003, pp. 376-381. doi:10.1046/j.1440-1827.2003.01484.x
[8] K. W. Chan, K. L. Chan and K. Y. Lam, “Inflammatory Pseudotumor of Epididymis and Epstein-Barr Virus: A Study of Two Cases,” Pathology, Vol. 29, No. 1, 1997, pp. 100-101.doi:10.1080/00 313029700169664
[9] J. M. Meis-Kindblom, C. Kjellstrom and L. G. Kindblom, “Inflammatory Fibrosarcoma: Update, Reappraisal, and Perspective on Its Place in the Spectrum of Inflammatory Myofibroblastic Tumors,” Seminars in Diagnostic Pathology, Vol. 15, No. 2, 1998, pp. 133-143.
[10] A. Freeman, N. Geddes, P. Munson, J. Joseph, P. Ramani, A. Sandison, C. Fisher and M. C. Parkinson, “Anaplastic Lymphoma Kinase (ALK 1) Staining and Molecular Analysis in Inflammatory Myofibroblastic Tumours of the Bladder: A Preliminary Clinicopathological Study of Nine Cases and Review of the Literature,” Modern Pathology, Vol. 17, No. 7, 2004, pp. 765-771. doi:10.1038/mo dpathol.3800078
[11] K. A. Iczkowski, J. H. Shanks, V. Gadaleanu, L. Cheng, E. C. Jones, R. Neumann, A. G. Nascimento and D. G. Bostwick, “Inflammatory Pseudotumor and Sarcoma of Urinary Bladder: Differential Diagnosis and Outcome in Thirty-Eight Spindle Cell Neoplasms,” Modern Pathology, Vol. 14, No. 10, 2001, pp. 1043-1051. doi:10.1038/modpathol.3880434

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.